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Charles J. Homer, MD, MPH,1 Suzette O. Oyeku, MD, MPH2The U.S. has made enormous progress in the care ofpeople with sickle cell disease (SCD) over the past 4decades. Even in the absence of the discovery of
new medications, median survival has increased dramati-
cally from death typically occurring during early childhood
in the 1970s to survival now in the mid-50s for individuals
with hemoglobin SS and mid-60s for individuals with
hemoglobin SC disease.1,2 This progress has been made
possible through universal newborn screening, the effective
use of penicillin, and more recently of hydroxyurea, careful
monitoring, and the provision of supportive care. Since the
publication of the commentary “Sickle Cell Disease: A
Question of Equity and Quality,” increased federal support
for and attention to sickle cell programs have spurred
clinical innovation and research initiatives as detailed in
several papers in this supplement.3 Yet, as these papers also
indicate, there is much further to go before all individuals
with SCD consistently receive high-quality, equitable care.
Population-level data presented in this supplement
indicate that only roughly one third of children were
receiving appropriate monitoring with transcranial Dop-
pler by age 2 years; one quarter of children at that age had
not received pneumococcal vaccine.4 In another state,
although increasing over time (consistent with increas-
ingly strong data supporting its use in young childhood),
rates of hydroxyurea use were less than 50%, varied across
sites, and rarely covered much more than half a year.5
These are not indicators of a high-reliability system.
Yet, alongside these data conveying serious short-
comings in care are two beacons indicating what is
possible. One report, from a community health center
based intervention in Tennessee, notes that 98% of
eligible patients were receiving hydroxyurea and that,
correspondingly, rates of vaso-occlusive crises were half
of published population norms.6 The other, a morefﬁce of the Assistant Secretary for Planning and Evaluation,
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how through the careful, unglamorous work of constant
improvement and innovation, testing and re-testing, the
sickle cell program at Cincinnati Children’s Hospital
Medical Center was able to improve its rate of transcra-
nial Doppler screening at age 2 years from 25% to 100%
and to maintain that high rate over a 20-month period.7
These reports indicate that with leadership, attention
to detail, monitoring of performance, and a disciplined
approach to continuous improvement, the health system
can achieve highly reliable care for patients within its
system and, correspondingly, achieve outstanding
results. Such high levels of performance rebut any
objection that says care is too complex or the patient
population too demanding to achieve this type of result.
However, taken as a whole, the papers in this issue
highlight that even when patients in some delivery
systems get nearly perfect care, a critical challenge at
the population level remains. This challenge is how to
link patients to these types of high-performing systems
and establish mechanisms to monitor at the population
level whether or not patients and families are getting the
care they need. Indeed, there is a close analogy between
this challenge and that identiﬁed in studies of racial
disparities in childhood cancer outcomes—children in
high-performing cancer treatment systems may have few
disparities, but across the entire population, minority or
disadvantaged children have worse outcomes because
they are less likely to be connected to such systems.8
The enormous effort several of the investigators needed
to undertake to collect the required data for their reports
is a credit to their initiative and the vision behind federal
initiatives such as the Registries and Surveillance System
for Hemoglobinopathies program. At the same time, these
reports highlight how fragmented the “system” is or, more
accurately, that there is no truly functional health system
that identiﬁes, links, monitors, and continuously improves
care and outcomes for individuals and the population as a
whole. There is not at the population level the same type
of leadership, attention to detail, monitoring, and focus on
continuous improvement that characterizes the programs
within clinical care delivery systems.
The vision for what such a program should look like is
quite clear and has been articulated by the Long-Term
Follow-Up Sub-Committee of the Secretary’s AdvisoryMedicine. This is an
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Children. That subcommittee has noted in a series of
reports that the purpose of any newborn screening
program is to improve the survival and well-being of
individuals with speciﬁc genetic conditions (e.g., SCD);
that achieving this requires not only rapid and reliable
diagnosis but also provision of evidence-based care,
coordination, and integration of a full range of holistic
services to meet child and family needs; and mechanisms
for continuous monitoring, improvement, and innova-
tion.9 Although some State public health agencies have
made strides, progress is limited and variable.10
Numerous barriers impede achieving this population
health vision, including lack of public health resources,
limits in interoperability of data systems, prioritizing
such relatively rare conditions, and lack of clear authority
and leadership. Having such a system in place would not
guarantee that the challenges that the data in this
supplement and elsewhere convey, for example, the lack
of providers with the knowledge, skills, and willingness to
treat adults with SCD, would be addressed successfully.
Nonetheless, such a system would make the shortcom-
ings immediately apparent and provide a rallying cry and
focus for addressing them. The expansion in health
insurance, particularly in states that have expanded
Medicaid should remove some of these latter barriers,
as should the substantial expansion in Federally Qualiﬁed
Community Health Centers. The emphasis of the
Health Resources and Services Administration’s Sickle
Cell Disease Treatment Demonstration Program on both
establishing effective data systems and increasing access
to skilled providers is another important contribution.
The reports in this issue demonstrate that true
excellence in clinical care and outcomes can be achieved
and that population data can be used to monitor quality
for individuals with SCD. What is needed now is a
concerted effort to have all providers perform at the level
of the two sites highlighted here and to have public healthsystems monitor and continuously improve care and
outcomes for patients with SCD as part of daily work so
that none are left behind.
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